Alyteserin-2a-Sp1

General Information


DRACP ID  DRACP05876

Peptide Name   Alyteserin-2a-Sp1

Sequence  ILGKLLⓍTAAⓍLLSNL

Sequence Length  16

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Stapled Peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=4.9±0.91 μM CCK-8 assay 72 h 1
U87 Glioblastoma Blastoma IC50=9.8±0.11 μM CCK-8 assay 72 h 1
A549 Lung adenocarcinoma Carcinoma IC50=3.6±1.0 μM CCK-8 assay 72 h 1
MDA-MB-231 Breast adenocarcinoma Carcinoma IC50=1.6μM CCK-8 assay 72h Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  48.3

Linear/Cyclic  Cyclic (Stapled)

Disulfide/Other Bond  Stapled: Ⓧ are cross-linked by hydrocarbon stapling

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  Ⓧ=(S)-2-(4-pentenyl)alanine (S5)

Chiral  L



Physicochemical Information


Formula  C67H118N16O16

Absent amino acids  CDEFHMPQRVWY

Common amino acids  L

Mass  167153

Pl  9.7

Basic residues  1

Acidic residues  0

Hydrophobic residues  9

Net charge  1

Boman Index  2084

Hydrophobicity  135

Aliphatic Index  183.13

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 34989078

Title  Hydrocarbon stapling modification of peptide alyteserin-2a: Discovery of novel stapled peptide antitumor agents

Doi 10.1002/psc.3401

Year  2022

Patent

Patent ID CN115160406A

Patent Title  Preparation method and application of novel anti-tumor cyclic peptide active molecules

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.